Latest filingSep 02, 2026Most recent Form 4
QNRX
Quoin Pharmaceuticals, Ltd.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying—8 buys
Total selling$00 sells
Net open-market—5 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period10transactions
- P · Open-market buys · dominant8 · 80%
- A · Grants / awards2 · 20%
Activity by reported role
A joint filing can contribute to multiple roles10transactions
- Director · dominant4 · 40%
- Chief executive officer2 · 20%
- Chief financial officer2 · 20%
- COO2 · 20%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (5)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeCulverwell Anthony JamesADSs · Direct
40,364Aug 31, 2026
Langer DennisADSs · Direct
56,243Aug 27, 2026
Culverwell Anthony JamesOrdinary Warrants (Right to Buy) · Direct
3,073Aug 31, 2026
Lawlor Sally BridgetOrdinary Warrants (Right to Buy) · Direct
5,122Aug 31, 2026
Lawlor Sally BridgetADSs · Direct
10,684Aug 31, 2026
Myers MichaelADSs · Direct
37,713Aug 31, 2026
Myers MichaelOrdinary Warrants (Right to Buy) · Direct
10,245Aug 31, 2026
Carter Denise P.ADSs · Direct
37,709Aug 31, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 03 → Sep 03
LessMore
Top insiders
By absolute net value across the selected period- CP+$100.0k
- MM+$100.0k
- LB+$50.0k
- CJ+$30.0k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
QNRX transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| QNRX | Carter Denise P. | COO | buy | 10.2k | — | P | 0.0% | 09/02 | 08/31 | |
| QNRX | Carter Denise P. | COO | buy | 20.4k | $9.99M | P | 0.0% | 09/02 | 08/31 | |
| QNRX | Myers Michael | CEO | buy | 10.2k | — | P | 0.0% | 09/02 | 08/31 | |
| QNRX | Myers Michael | CEO | buy | 20.4k | $9.99M | P | 0.0% | 09/02 | 08/31 | |
| QNRX | Lawlor Sally Bridget | CFO | buy | 5.12k | — | P | 0.0% | 09/02 | 08/31 | |
| QNRX | Lawlor Sally Bridget | CFO | buy | 10.2k | $4.99M | P | 0.0% | 09/02 | 08/31 | |
| QNRX | Culverwell Anthony James | DIR | buy | 3.07k | — | P | 0.0% | 09/02 | 08/31 | |
| QNRX | Culverwell Anthony James | DIR | buy | 6.14k | $2.99M | P | 0.0% | 09/02 | 08/31 |
Quoin Pharmaceuticals, Ltd. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Quoin Pharmaceuticals, Ltd.?
Carter Denise P., Myers Michael, Lawlor Sally Bridget, Culverwell Anthony James, LANGER DENNIS.
When was the latest reported open-market purchase?
Carter Denise P. reported a buy on Aug 31, 2026 valued at an unknown value. Read the SEC filing.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
The net open-market value is unknown because at least one matching code-P or code-S row lacks a value.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.